# To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability

> **NCT05856058** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 16 (actual)

## Conditions studied

- Graft-versus-host Disease

## Interventions

- **DRUG:** SHR0302

## Key facts

- **NCT ID:** NCT05856058
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-29
- **Primary completion:** 2023-07-03
- **Final completion:** 2023-10-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05856058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05856058, "To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05856058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*